Vor Biopharma Inc.

8-K · vor-20260608.htm iXBRL

0001817229 2026-06-08 2026-06-08

  
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): June 08, 2026

  
  
 VOR BIOPHARMA INC.
 (Exact name of Registrant as Specified in Its Charter)
  
  

 Delaware

 001-39979

 81-1591163

 (State or Other Jurisdiction
of Incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

  

  

  

  

  

 500 Boylston Street, Suite 1350

  

 Boston , Massachusetts

  

 02116

 (Address of Principal Executive Offices)

  

 (Zip Code)

  

 Registrant’s Telephone Number, Including Area Code: 617 655-6580

  

  

 (Former Name or Former Address, if Changed Since Last Report)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

 Trading
Symbol(s)

  

Name of each exchange on which registered

 Common Stock, $0.0001 par value per share

  

 VOR

  

 Nasdaq Global Select Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  

 Item 7.01 Regulation FD Disclosure.
 On June 8, 2026, Vor Biopharma Inc. (the “Company”) announced that RemeGen Co., Ltd. received conditional approval from the National Medicinal Products Administration (“NMPA”) for telitacicept for the treatment of adult patients with IgA nephropathy and approval from the NMPA for telitacicept for the treatment of adult patients with Sjögren’s disease, in each case in China. A copy of the Company's press releases are furnished as Exhibits 99.1 and 99.2.
  
 The information contained in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
 Item 9.01 Financial Statements and Exhibits.

 Exhibit No.

  

 99.1

 Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

 99.2

 Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

 104

 Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

  

 Vor Biopharma Inc.

  

  

  

  

 Date:

 June 8, 2026

 By:

 /s/ Jean-Paul Kress

  

  

  

 Jean-Paul Kress
Chief Executive Officer